The largest database of trusted experimental protocols

Ubistesin

Manufactured by 3M
Sourced in Italy

Ubistesin is a local anesthetic product developed by 3M for use in medical and dental procedures. It contains the active ingredient lidocaine hydrochloride, which is a commonly used local anesthetic. The core function of Ubistesin is to provide temporary numbness or loss of sensation in a specific area of the body to enable various medical or dental treatments to be carried out comfortably and painlessly.

Automatically generated - may contain errors

2 protocols using ubistesin

1

Atraumatic Extraction and Immediate Implant Placement

Check if the same lab product or an alternative is used in the 5 most similar protocols
All surgical procedures were performed by a single operator (PC).
After local anesthesia with articaine hydrochloride 1:100,000 (Ubistesin 40 mg/mL, 3M ESPE, Milan, Italy), the hopeless teeth were extracted a-traumatically, maintaining the integrity of the fresh socket and, specifically, the buccal bone wall (Figure 2).
A periodontal probe (Hu-Friedy PGF-GFS, Hu-Friedy, Chicago, IL, USA) was used to confirm the integrity of the four socket walls. All experimental sites displayed no fenestration or dehiscence, and no regenerative procedures were completed at any of the sites.
The implant sites were prepared according to the manufacturer’s (CSR implant System, Sweden & Martina, Due Carrare, Padua, Italy) surgical protocol, with standard drills following the palatal wall as a guide, and the apical portion of the implant was prepared 4 mm beyond the apex of the root.
The coronal margin of the implant was located at 0.5 mm apically to the buccal level of the bone crest.
The quality of alveolar bone was evaluated during surgery for each site.
If the gap between implant surfaces and socket walls exceeded 2 mm, small autogenous bone chips were inserted in that space.
+ Open protocol
+ Expand
2

Anesthetic Agents Comparison in Dentistry

Check if the same lab product or an alternative is used in the 5 most similar protocols
The commercial anesthetic drugs used in this study were articaine-based agents: Ubistesin (522721, 3 M ESPE), Ubistesin forte (512987, 3 M ESPE), Septanest (09091451103, Septodont) and mepivacaine-based agent: Scandonest (09091173002, Septodont) and Lidocaine based agent: Xylocaine (Batch 4180, Dentsply).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!